CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
autologous bone marrow mononuclear cells +1 morebiological
Likely dose
autologous bone marrow mononuclear cells 25mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01028794
NCT01028794Phase 2Completed
CompareCT.gov

Phase 1/2A Study of Intravenous Autologous Bone Marrow Mononuclear Cell Transplantation for Patients After Cerebral Embolism

National Cerebral and Cardiovascular Center, Japan·interventional·Posted Dec 9, 2009·Updated Jul 8, 2013

In Brief

A Phase 2 clinical trial evaluating autologous bone marrow mononuclear cells for Cerebral Embolism and Stroke. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether autologous bone marrow mononuclear cells transplantation after stroke is safe and/or effective to improve neurological outcome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCerebral Embolism, Stroke
CountriesJapan
CollaboratorsInstitute of Biomedical Research and Innovation, Kobe, Hyogo, Japan

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 9, 2009
Enrollment StartMay 1, 2008
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 16.6 years ago

Interventions

autologous bone marrow mononuclear cellsbiological

intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)

autologous bone marrow mononuclear cellsbiological

intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)